Experience and efficacy of SBRT for lung cancer:an analysis of 200 patients
10.3760/cma.j.issn.1004-4221.2017.06.004
- VernacularTitle:200例肺部肿瘤SBRT的经验和疗效
- Author:
Baiqiang DONG
;
Yujin XU
;
Xiaojiang SUN
;
Xiao ZHENG
;
Xianghui DU
;
Xiaoyun DI
;
Guoping SHAN
;
Weijun CHEN
;
Pu LI
;
Jianlong LI
;
Kainan SHAO
;
Yaping XU
;
Ming CHEN
- Keywords:
Lung neoplasms/stereotactic body radiation therapy;
Isolated pulmonary metastasis/stereotactic body radiation therapy;
Treatment outcome
- From:
Chinese Journal of Radiation Oncology
2017;26(6):627-630
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the safety and clinical efficacy of stereotactic body radiation therapy (SBRT) for lung cancer.Methods A retrospective analysis was performed on 200 patients with primary non-small cell lung cancer (NSCLC)(118 patients) or solitary pulmonary metastasis (82 patients) who underwent SBRT in Zhejiang Cancer Hospital from January 2012 to September 2015.The 80% isodose line covered 95% of the planning target volume,and the 100% isodose line covered 100% of the internal gross tumor volume.The fractional dose was 4.0-18.0 Gy daily or every other day,and the biologically equivalent dose ranged from 40.0 to 151.2 Gy (median 100 Gy).Results All patients completed treatment.The follow-up rate was 96.0%.The complete response and partial response rates were 14.8%(17/115) and 65.2%(75/115) for the primary tumor group,versus 25%(19/77) and 38%(29/77) for the metastasis group.The incidence rates of grade Ⅱ and Ⅲ acute radiation pneumonitis were 4.7% and 3.1%,respectively.The median follow-up was 14.9 months.The 1-and 2-year local control rates were 95.7% and 84.3% for the primary tumor group,versus 92% and 73% for the metastasis group.The 1-and 2-year overall survival rates were 94.5% and 92.0% for the primary tumor group,versus 85% and 62% for the metastasis group.Conclusions SBRT is a safe and effective treatment for early primary NSCLC and solitary pulmonary metastasis,resulting in high 1-and 2-year local control and overall survival rates and low rate of complications.
